AbbVie Inc’s Raised Bid Confirms My Shire PLC Sell Rating

Shire PLC (LON:SHP) shares are sliding following AbbVie Inc (NYSE: ABBV)’s increased bid, confirming this Fool’s previous sell call.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

shireLast Friday, I explained why I thought Shire (LSE: SHP) (NASDAQ: SHPG.US) shareholders should sell their shares, regardless of the possibility of an increased bid from US pharma firm AbbVie.

Earlier today, AbbVie did submit a raised bid — so was I wrong?

I still say sell

AbbVie’s raised bid is for £22.44 in cash and 0.8568 AbbVie shares for each Shire share. This equates to around £51 at today’s exchange rates.

The offer is an 11% increase on the previous £46 proposal, but interestingly, Shire’s share price has not budged following the news — indeed, as I write, Shire share price has started to fall, and is now down by 3% on this morning’s opening price.

What’s happening?

AbbVie claims to have “met with, or spoken to” Shire shareholders who represent the majority of Shire’s outstanding shares.

However, the fact that Shire’s share price has fallen following the new offer seems to suggest that the City doesn’t expect Shire’s management to take up the offer, increasing the chances that the bid will fall through by the 18 July  deadline.

Indeed, having looked at the details of the offer, I can see several problems with AbbVie’s new bid, which could explain the market’s lack of interest.

Not enough cash

Although this deal would have tax advantages for AbbVie, it might not do for Shire’s largest, long-term shareholders, who could face substantial capital gains tax bills.

Less than half the offer is in cash, so large UK shareholders would also be left with a big pile of AbbVie’s US-listed shares. In many cases, UK funds would be forced to sell these US shares straight after the deal went through, which would depress the price of AbbVie shares, reducing the real value of AbbVie’s offer.

Private shareholders in the UK would experience the same problems, and would face US share dealing and foreign exchange costs, too.

In my view, it seems fair to say that the true value of AbbVie’s revised offer, to most shareholders, is likely to be much less than £51.

Challenging valuation

A second problem is that Shire’s current share price places a seriously ambitious valuation on Shire’s business — around 23 times 2014 forecast earnings.

Shire shares trade at a premium of more than 20% to their pre-bid price, and have risen by 450% since 2009. For most shareholders, I think it’s time to take profits, de-risk, and sell — because Shire shares could plummet if the AbbVie bid fails.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Roland does not own shares in any of the companies mentioned in this article. The Motley Fool has recommended shares in Shire.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »